GORT

Reviews

Cathie Wood Darling Exact Sciences, And Rival Guardant Health

Di: Everly

Your cart is currently empty. Visit the IBD Store to get started.

Exact Sciences (EXAS), a large holding of Cathie Wood’s ARK Innovation fund, came in hot with double-digit sales growth that easily beat third-quarter projections. But EXAS

Combined Holdings of EXAS in All ARK ETFs

Cathie Wood Boosts Coinbase, Tesla Holdings, Cuts Back Exact Sciences

Exact Sciences makes Cologuard, a stool-based test that screens for colorectal cancer. Last summer, the Food and Drug Administration approved rival Guardant Health’s blood test for

Exact Sciences (EXAS) stock tumbled early Thursday in a move analysts called „overdone“ and „overblown“ as fears of a sales slowdown spooked investors in the Cologuard

Exact Sciences (EXAS) reported its sixth consecutive quarter of double-digit sales growth, but screening revenue missed whispered expectations and EXAS stock plummeted

  • Exact Sciences Stock Drops 12% Over Four Days. ‚What Is Going On?‘
  • Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
  • Can This Beaten-Down Cathie Wood Stock Bounce Back?
  • Cathie Wood: 19 Exact Sciences transactions

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet.

Colon cancer blood test competition spills over to social media

ARKK’s Top Bet: Thanks to the rally, Madison, Wisconsin-based Exact Sciences has become the top holding of Cathie Wood-led Ark Invest’s flagship exchange-traded fund.

DeepSeek’s rise has spotlighted AI in healthcare. Cathy Wood sees healthcare as an underappreciated AI sector with huge potential in drug development and diagnostics. Pelosi’s SEC filing revealed an investment in

Cathie Wood bought shares of Guardant Health, Oklo, and CRISPR Technologies on Tuesday. Guardant is the only one of the three trading higher this year, fueled by the prospects of a new

Over the weekend, during the lead-up to Exact Sciences announcing data from a blood-based colon cancer test, Guardant Health co-CEO AmirAli Talasaz challenged Exact’s CEO, Kevin Conroy,

2. Guardant Health. Guardant is another Cathie Wood stock that stands to grow into the huge market for preventative cancer screening. The company uses proprietary blood

Exact Sciences has long persisted on Cathie Wood’s ARK Innovation (ARKK) exchange-traded fund. Wall Street has long feared blood-based colon cancer tests would replace stool-based tests.

If the projection proves true, three of her portfolio’s companies– Pacific Biosciences (PACB-3.63%), Guardant Health (GH-2.96%), and Exact Sciences (EXAS 0.12%)– could be

Cathie Wood: 20 Guardant Health transactions

Benzinga.com — Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings . News • May 1, 2025. Business

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet.

  • Guardant Health And The Blood Test Revolution
  • Combined Holdings of EXAS in All ARK ETFs
  • 3 Cathie Wood Stocks for a $150 Billion Market That’s Just FormingCathie Wood Is Selling This Stock: Should You?
  • Colon cancer blood test competition spills over to social media

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates. Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists.

Ahead of the ESMO presentation, Guardant Health co-founder and co-CEO AmirAli Talasaz said in a LinkedIn post over the weekend he would “publicly bet” Conroy $1

Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences‘ shares are up more than 31% so far this year, while

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates. Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists. Watch IBD’s Investing Strategies

What is Wrong with Exact Sciences?

That’s the case with Cathie Wood, CEO of Ark Invest, an investment management firm. Wood’s firm recently sold thousands of shares of cancer diagnostics specialist Exact Sciences (EXAS 3.51%

19 Cathie Wood Exact Sciences Trades Cathie Wood’s position in Exact Sciences is currently worth $1.86 Thousand. That’s 0.00% of their equity portfolio (177th largest holding). Cathie

Exact Sciences makes Cologuard, a stool-based test that screens for colorectal cancer. Last summer, the Food and Drug Administration approved rival Guardant Health’s blood test for

After a patient is diagnosed with cancer, the most common route is to attack it with surgery. Guardant Health, Exact Sciences and Natera can run that sample through their

Exact Sciences stock fell early Thursday after the company said its next-generation Cologuard beat a rival stool-based screening test.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

All 20 Guardant Health Inc (GH) purchases and sells made by Cathie Wood (ARK Invest). Latest and historical data Chart of GH price

Cathie Wood is one of them. The investment firm she heads, Ark Invest, holds over 330,000 shares of Exact Sciences. She isn’t the only one who isn’t giving up on the company.

Exact Sciences stock crumbled Thursday — extending its losses this week — on its growing rivalry with Guardant Health and Natera in colon cancer screening. Despite a promising

This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street . Prosper Junior Bakiny, The Motley Fool. July 8, 2024 at 5:30 AM. Copied; To say that Exact

Exact Sciences Corporation is a molecular diagnostics company specializing in the detection and prevention of certain types of cancer. The company makes money by developing

The latest issue of the New England Journal of Medicine featured a duet of expansive studies from Guardant Health and Exact Sciences, examining their upcoming tests